BRPI1010621A2 - derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso - Google Patents
derivado de imidazoquinolinonas, sua composição farmacêutica e seu usoInfo
- Publication number
- BRPI1010621A2 BRPI1010621A2 BRPI1010621A BRPI1010621A BRPI1010621A2 BR PI1010621 A2 BRPI1010621 A2 BR PI1010621A2 BR PI1010621 A BRPI1010621 A BR PI1010621A BR PI1010621 A BRPI1010621 A BR PI1010621A BR PI1010621 A2 BRPI1010621 A2 BR PI1010621A2
- Authority
- BR
- Brazil
- Prior art keywords
- imidazoquinolinones
- derivative
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
- HOPZBJPSUKPLDT-UHFFFAOYSA-N imidazo[4,5-h]quinolin-2-one Chemical class C1=CN=C2C3=NC(=O)N=C3C=CC2=C1 HOPZBJPSUKPLDT-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18414109P | 2009-06-04 | 2009-06-04 | |
| PCT/EP2010/057719 WO2010139731A1 (en) | 2009-06-04 | 2010-06-02 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1010621A2 true BRPI1010621A2 (pt) | 2016-06-21 |
Family
ID=42697442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1010621A BRPI1010621A2 (pt) | 2009-06-04 | 2010-06-02 | derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US8476294B2 (OSRAM) |
| EP (1) | EP2438064A1 (OSRAM) |
| JP (1) | JP5596137B2 (OSRAM) |
| KR (1) | KR101445458B1 (OSRAM) |
| CN (1) | CN102574845B (OSRAM) |
| AR (1) | AR076949A1 (OSRAM) |
| AU (1) | AU2010255727B2 (OSRAM) |
| BR (1) | BRPI1010621A2 (OSRAM) |
| CA (1) | CA2763821A1 (OSRAM) |
| CL (1) | CL2011003052A1 (OSRAM) |
| CO (1) | CO6470887A2 (OSRAM) |
| CR (1) | CR20110608A (OSRAM) |
| CU (1) | CU24064B1 (OSRAM) |
| DO (1) | DOP2011000373A (OSRAM) |
| EA (1) | EA020715B1 (OSRAM) |
| EC (1) | ECSP11011500A (OSRAM) |
| GE (1) | GEP20156267B (OSRAM) |
| IL (1) | IL216452A0 (OSRAM) |
| MA (1) | MA33332B1 (OSRAM) |
| MX (1) | MX2011012943A (OSRAM) |
| NI (1) | NI201100209A (OSRAM) |
| NZ (1) | NZ596487A (OSRAM) |
| PE (1) | PE20120224A1 (OSRAM) |
| SG (1) | SG176572A1 (OSRAM) |
| TN (1) | TN2011000626A1 (OSRAM) |
| TW (1) | TWI464168B (OSRAM) |
| UA (1) | UA106074C2 (OSRAM) |
| UY (1) | UY32682A (OSRAM) |
| WO (1) | WO2010139731A1 (OSRAM) |
| ZA (1) | ZA201108439B (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102010035744A1 (de) | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
| KR20140014104A (ko) * | 2010-12-06 | 2014-02-05 | 피라말 엔터프라이지즈 리미티드 | 치환된 이미다조퀴놀린 유도체 |
| JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
| US9284315B2 (en) | 2011-11-17 | 2016-03-15 | Zuanzhu Pharma Co., Ltd. | Three-ring PI3K and/or mTOR inhibitor |
| WO2014141118A1 (en) * | 2013-03-14 | 2014-09-18 | Piramal Enterprises Limited | Imidazo[4,5-c]quinoline derivatives and uses thereof |
| JP6419783B2 (ja) | 2013-04-15 | 2018-11-07 | エフ エム シー コーポレーションＦｍｃ Ｃｏｒｐｏｒａｔｉｏｎ | 殺菌・殺カビ性アミド |
| CN105531348B (zh) * | 2013-09-11 | 2017-11-07 | 默克专利有限公司 | 杂环化合物 |
| CN104513254B (zh) | 2013-09-30 | 2019-07-26 | 上海璎黎药业有限公司 | 稠合嘧啶类化合物、中间体、其制备方法、组合物和应用 |
| JP6606428B2 (ja) * | 2013-10-11 | 2019-11-13 | 国立大学法人 東京医科歯科大学 | 脊髄小脳変性症を予防又は治療するための薬剤 |
| CN104447740B (zh) * | 2013-11-20 | 2017-02-22 | 北京富龙康泰生物技术有限公司 | 咪唑酮类衍生物、其药物组合物和用途 |
| NO2714752T3 (OSRAM) | 2014-05-08 | 2018-04-21 | ||
| HRP20181670T1 (hr) | 2014-06-03 | 2018-12-14 | Idorsia Pharmaceuticals Ltd | Spojevi pirazola i njihova uporaba kao blokatora kalcijevih kanala t-tipa |
| HUE054745T2 (hu) * | 2015-04-02 | 2021-09-28 | Merck Patent Gmbh | Imidazolonilkinolinok és alkalmazásuk ATM-kináz-inhibitorokként |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| GB201519568D0 (en) * | 2015-11-05 | 2015-12-23 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| US10988472B2 (en) | 2016-10-13 | 2021-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compounds and method for blocking transmission of malarial parasite |
| EP3554490B1 (en) | 2016-12-16 | 2022-02-16 | Idorsia Pharmaceuticals Ltd | Pharmaceutical combination comprising a t-type calcium channel blocker |
| TWI808960B (zh) | 2017-02-06 | 2023-07-21 | 瑞士商愛杜西亞製藥有限公司 | 用於合成1-芳基-1-三氟甲基環丙烷之新穎方法 |
| JOP20190209A1 (ar) * | 2017-03-16 | 2019-09-12 | Astrazeneca Ab | مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان |
| JP7569688B2 (ja) | 2017-12-22 | 2024-10-18 | ハイバーセル，インコーポレイテッド | ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体 |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| CA3154475A1 (en) * | 2019-09-23 | 2021-04-01 | Nanjing Zhengxiang Pharmaceuticals Co., Ltd. | Phosphodiesterase inhibitors and use |
| WO2022060377A1 (en) * | 2020-09-21 | 2022-03-24 | Wei Zhong | Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability |
| US20230380203A1 (en) * | 2021-01-26 | 2023-11-23 | Boe Technology Group Co., Ltd. | Quantum dot light-emitting device, display apparatus and manufacturing method |
| CN116768928A (zh) * | 2023-06-15 | 2023-09-19 | 上海毕臣生化科技有限公司 | 一种3-叔丁基-5-硼酸酯基吡啶的合成方法 |
| CN117384154A (zh) * | 2023-09-04 | 2024-01-12 | 广州医科大学 | 一种吡咯并喹啉酮化合物、合成方法及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0211649D0 (en) * | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| BRPI0416801A (pt) | 2003-11-21 | 2007-01-09 | Novartis Ag | derivados de 1h-imidazoquinolina como inibidores de proteìna sinase |
| AR046845A1 (es) * | 2003-11-21 | 2005-12-28 | Novartis Ag | Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas |
| AU2005284835A1 (en) | 2004-09-14 | 2006-03-23 | Novartis Vaccines And Diagnostics Inc. | Imidazoquinoline compounds |
| GB0510390D0 (en) * | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| CN101309687A (zh) | 2005-11-04 | 2008-11-19 | 科勒制药集团公司 | 经羟基和烷氧基取代的1h-咪唑并喹啉及其方法 |
| MX2009005360A (es) | 2006-11-20 | 2009-06-05 | Novartis Ag | Sales y formas de cristal del 2-metil-2-[4-(3-metil-2-oxo-8-quinol in-3-il-2,3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propion itrilo. |
| KR101472607B1 (ko) | 2007-02-20 | 2014-12-15 | 노파르티스 아게 | 지질 키나제 및 ｍＴＯＲ의 이중 억제제로서의 이미다조퀴놀린 |
| PT2182948E (pt) * | 2007-07-24 | 2013-04-30 | Novartis Ag | Utilização de imidazoquinolinas para o tratamento de doenças dependentes do egfr ou doenças que adquiriram resistência a agentes que têm como alvo membros da família egfr |
| US20090082387A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched nvp-bez234 |
| CA2717948C (en) | 2008-03-26 | 2016-09-06 | Novartis Ag | 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes |
| US20110212053A1 (en) | 2008-06-19 | 2011-09-01 | Dapeng Qian | Phosphatidylinositol 3 kinase inhibitors |
| WO2010038165A1 (en) | 2008-09-30 | 2010-04-08 | Pfizer Inc. | Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions |
-
2010
- 2010-06-02 AU AU2010255727A patent/AU2010255727B2/en not_active Ceased
- 2010-06-02 BR BRPI1010621A patent/BRPI1010621A2/pt not_active IP Right Cessation
- 2010-06-02 UA UAA201114398A patent/UA106074C2/uk unknown
- 2010-06-02 EA EA201101704A patent/EA020715B1/ru not_active IP Right Cessation
- 2010-06-02 EP EP10721029A patent/EP2438064A1/en not_active Withdrawn
- 2010-06-02 CN CN201080034616.0A patent/CN102574845B/zh not_active Expired - Fee Related
- 2010-06-02 JP JP2012513613A patent/JP5596137B2/ja not_active Expired - Fee Related
- 2010-06-02 AR ARP100101942A patent/AR076949A1/es unknown
- 2010-06-02 NZ NZ596487A patent/NZ596487A/xx not_active IP Right Cessation
- 2010-06-02 KR KR1020127000098A patent/KR101445458B1/ko not_active Expired - Fee Related
- 2010-06-02 WO PCT/EP2010/057719 patent/WO2010139731A1/en not_active Ceased
- 2010-06-02 GE GEAP201012484A patent/GEP20156267B/en unknown
- 2010-06-02 MX MX2011012943A patent/MX2011012943A/es active IP Right Grant
- 2010-06-02 MA MA34404A patent/MA33332B1/fr unknown
- 2010-06-02 CA CA2763821A patent/CA2763821A1/en not_active Abandoned
- 2010-06-02 US US12/792,471 patent/US8476294B2/en not_active Expired - Fee Related
- 2010-06-02 PE PE2011002047A patent/PE20120224A1/es not_active Application Discontinuation
- 2010-06-02 SG SG2011085487A patent/SG176572A1/en unknown
- 2010-06-03 UY UY0001032682A patent/UY32682A/es not_active Application Discontinuation
- 2010-06-03 TW TW099117977A patent/TWI464168B/zh not_active IP Right Cessation
-
2011
- 2011-11-17 IL IL216452A patent/IL216452A0/en not_active IP Right Cessation
- 2011-11-17 ZA ZA2011/08439A patent/ZA201108439B/en unknown
- 2011-11-21 CR CR20110608A patent/CR20110608A/es unknown
- 2011-11-30 NI NI201100209A patent/NI201100209A/es unknown
- 2011-11-30 CU CU2011000221A patent/CU24064B1/es not_active IP Right Cessation
- 2011-12-02 DO DO2011000373A patent/DOP2011000373A/es unknown
- 2011-12-02 CL CL2011003052A patent/CL2011003052A1/es unknown
- 2011-12-02 EC EC2011011500A patent/ECSP11011500A/es unknown
- 2011-12-05 TN TNP2011000626A patent/TN2011000626A1/en unknown
- 2011-12-12 CO CO11170918A patent/CO6470887A2/es active IP Right Grant
-
2013
- 2013-05-24 US US13/901,849 patent/US20140005163A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1010621A2 (pt) | derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso | |
| BR112012013148A2 (pt) | formulação farmacêutica e uso | |
| BRPI0915552A2 (pt) | derivados de ciclosporina, seu uso e sua composição farmacêutica | |
| BRPI0917315A2 (pt) | anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica | |
| BRPI1008045A2 (pt) | derivados de aminotetralina, composições farmacêuticas contendo-os, e seu uso em terapia | |
| BR112013016772A2 (pt) | composto, uso do composto, composição farmacêutica, oligonucleotídeo e conjugado | |
| HRP20160579T1 (hr) | Spoj indola i njegova farmaceutska upotreba | |
| BR112012031226A2 (pt) | composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica | |
| BRPI1009372A2 (pt) | compostos, composição farmacêutica e respectivos usos | |
| BRPI1016219A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI1008793A2 (pt) | composto, uso de um composto, e, composição farmacêutica | |
| BRPI1013642A2 (pt) | derivado de triazina e composição farmacêutica compreendendo o mesmo | |
| BRPI0721651A2 (pt) | Composição farmacêutica | |
| BR112012004335A2 (pt) | composto, composição farmacêutica, e, uso do composto. | |
| BRPI0821115A2 (pt) | Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto | |
| EP2451274A4 (en) | Pharmaceutical compositions | |
| EP2419097A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| BRPI1010024A2 (pt) | derivados de aminopirrolidinona e uso dos mesmos | |
| DK2391349T3 (da) | Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater | |
| BRPI1014914A2 (pt) | Composição contendo trehalulose, sua preparação e uso | |
| IT1403847B1 (it) | Composizioni farmaceutiche comprendenti rifaximina e loro uso. | |
| BRPI0807078A2 (pt) | Composto, e, formulação farmacêutica | |
| BR112012000831A2 (pt) | compostos, composições farmacêuticas e métodos relacionados | |
| BRPI1006953A2 (pt) | composição farmacêutica, e, uso de uma composição | |
| BRPI0907228A2 (pt) | Compostos de tienopiridazina, suas preparações, composições farmacêuticas e usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |